Quidel Corporation develops, manufactures, and markets diagnostic testing solutions for applications primarily in infectious diseases, womens health, and gastrointestinal diseases. The company was founded in 1979 and is based in San Diego, California.
QDEL Price Forecast Based on DCF Valuation
DCF Fair Value Target:
The table below illustrates the output of a discounted cash flow forecast using a variety of scenarios for Quidel Corp. To summarize, we found that Quidel Corp ranked in the 64th percentile in terms of potential gain offered. More precisely, our analysis suggests the stock is undervalued by approximately 136.5% on a DCF basis. In terms of the factors that were most noteworthy in this DCF analysis for QDEL, they are:
The stock's equity weight, or the proportion of capital from equity relative to debt, is 98. Its equity weight surpasses that of 85.38% of free cash flow generating stocks in the Healthcare sector.
The business' balance sheet suggests that 2% of the company's capital is sourced from debt; this is greater than only 7.14% of the free cash flow producing stocks we're observing.
QDEL's estimated cost of debt, based largely on its market capitalization and its interest coverage ratio, is 2%; for context, that number is higher than 50.47% of tickers in our DCF set.
Terminal Growth Rate in Free Cash Flow
Return Relative to Current Share Price
DVA, AHPI, BKD, HCSG, and PBH can be thought of as valuation peers to QDEL, in the sense that they are in the Healthcare sector and have a similar price forecast based on DCF valuation.
The latest 13F reporting period has come and gone, and Insider Monkey have plowed through 823 13F filings that hedge funds and well-known value investors are required to file by the SEC. The 13F filings show the funds' and investors' portfolio positions as of June 30th, when the S&P 500 Index was trading around the […]
Shares of COVID-19 vaccine developer Vaxart (NASDAQ: VXRT) and coronavirus diagnostic test manufacturers Opko Health (NASDAQ: OPK) and Quidel (NASDAQ: QDEL) plunged more than 35% in August, according to data provided by S&P Global Market Intelligence. Vaxart's shares were down 36.9%, Opko's fell 37.1%, and Quidel's dropped 37.7% for the month. Opko's and Quidel's shares are up more than 100% so far in 2020, while Vaxart's have risen a jaw-dropping 1,300%.